Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors

MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief...
March 01, 2021 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in...
February 25, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
February 24, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer

-- Brings more than two decades of executive management experience from global pharmaceutical companies -- MOUNTAIN VIEW, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:...
February 23, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021

MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released...
February 17, 2021 17:00 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan’s...
January 06, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Participate in Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
December 21, 2020 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatmentThe change from baseline...
November 19, 2020 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...
November 09, 2020 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights

-- New Drug Application (NDA) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA-associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing...